Abstract: Osunprotafib, also known as ABBV-CLS-484 (AC484), is a first-in-class, orally bioavailable, small-molecule active-site inhibitor of the protein tyrosine phosphatases PTPN2 and PTPN1. These phosphatases act as critical negative regulators of inflammation, dampening Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and T cell receptor (TCR) signaling pathways. By inhibiting PTPN2/N1, AC484 profoundly sensitizes tumors to interferon-gamma (IFNγ) and unleashes robust anti-tumor immunity across multiple immune cell subsets, including CD8+ T cells, natural killer (NK) cells, and macrophages. In the context of adoptive cell therapy (ACT), ex vivo treatment of T cells with AC484 induces epigenetic, transcriptional, and metabolic reprogramming that mitigates T cell exhaustion and enhances polyfunctionality, metabolic fitness, and in vivo persistence. AC484 demonstrates potent monotherapy efficacy in PD-1-resistant preclinical models and is currently under clinical evaluation, representing a significant breakthrough in targeting traditionally "undruggable" phosphatase active sites for cancer immunotherapy.
1. Introduction
Immune checkpoint blockade has revolutionized cancer treatment, yet a significant proportion of patients remain refractory to current immunotherapies, necessitating the development of novel therapeutic strategies to overcome resistance [1]. The protein tyrosine phosphatases PTPN2 (TC-PTP) and its paralogue PTPN1 (PTP-1B) have emerged as central negative regulators of inflammation. They function by dephosphorylating members of the JAK and STAT families, as well as key components of the T cell receptor (TCR) signaling cascade, thereby acting as crucial checkpoints that limit immune activation [1]. Genetic deletion of PTPN2 or PTPN1 in either tumor cells or immune cells has been shown to promote anti-tumor immunity [1].
Historically, phosphatases have been considered highly challenging drug targets—often deemed "undruggable"—due to their highly polar active sites, which typically require highly polar inhibitors that suffer from poor cellular permeability and pharmacokinetic properties [1]. Osunprotafib (ABBV-CLS-484 or AC484) represents a major pharmacological breakthrough as a first-in-class, orally bioavailable, potent active-site inhibitor of both PTPN2 and PTPN1 [1]. AC484 is currently being evaluated in Phase I clinical trials (ClinicalTrials.gov identifier NCT04777994) for patients with advanced solid tumors, marking the first active-site phosphatase inhibitor to enter clinical evaluation for cancer immunotherapy [1].
2. Pharmacological Activity
AC484 exhibits broad and potent pharmacological activity by acting directly on both tumor cells and immune cells. In vitro, AC484 dose-dependently inhibits the growth of various human cancer cell lines, strictly in the presence of IFNγ, by amplifying the IFNγ-sensing pathway [1]. It also enhances the activation and effector functions of human and murine T cells and NK cells, increasing the production of cytokines such as IFNγ, TNF, and chemokines like CXCL9 and CXCL10 [1].
In vivo, systemic administration of AC484 induces highly significant tumor regression and increases survival in multiple syngeneic mouse models, including B16 melanoma, KPC pancreatic adenocarcinoma, and the PD-1-resistant 4T1 and EMT-6 breast carcinoma models [1]. AC484 treatment inflames the tumor microenvironment (TME), driving a significant expansion in the relative frequencies of CD8+ T cells and NK cells, increasing the M1 to M2 macrophage ratio, and promoting deeper immune cell infiltration into the tumor bed [1].
Importantly for Adoptive Cell Therapy (ACT), AC484 demonstrates profound utility in enhancing T cell products ex vivo. In an EL4-OVA adoptive cell therapy model, OT-I CD8+ T cells that were expanded in vitro in the presence of AC484 and subsequently adoptively transferred into tumor-bearing mice exhibited superior tumor suppression compared to vehicle-treated T cells, with a significant proportion of mice achieving complete responses even after the drug was washed out prior to transfer [1]. This indicates that transient PTPN2/N1 inhibition imparts durable functional enhancements to engineered or adoptively transferred T cells.
3. Molecular Mechanism of Action
The molecular mechanism of AC484 is rooted in the amplification of JAK-STAT and TCR signaling pathways. By inhibiting PTPN2 and PTPN1, AC484 prevents the dephosphorylation of key signaling molecules. In T cells, AC484 treatment enhances TCR signaling (evidenced by increased phosphorylation of LCK and FYN) and cytokine signaling, particularly the IL-2–STAT5 and IFNγ–STAT1 pathways [1].
This enhanced signaling drives profound epigenetic and transcriptional reprogramming in CD8+ T cells. AC484 reduces the expression of terminal exhaustion markers such as TOX, PD-1, and TIM-3, while simultaneously enriching gene signatures associated with memory and effector functions (e.g., TCF7, IL7R, SELL, LEF1, and GZMB) [1]. The transcriptional state induced by AC484 closely phenocopies the effects of combined IL-2 and anti-PD-L1 therapy [1].
Furthermore, AC484 significantly boosts the metabolic fitness of T cells. Seahorse assays reveal that AC484 increases both the maximal oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) in activated T cells, indicating enhanced mitochondrial oxidative phosphorylation and glycolytic metabolism. This is accompanied by an overall increase in mitochondrial mass, which is critical for the survival, persistence, and polyfunctionality of T cells in the hostile TME [1].
4. Structure-Activity Relationship (SAR)
The discovery of AC484 overcame the historical challenge of drugging the highly polar phosphatase active site. AC484 achieves low nanomolar biochemical potency against both PTPN2 (IC50 = 1.8 nM) and PTPN1 (IC50 = 2.5 nM) through a highly optimized network of ligand-target interactions [1].
Structural crystallography reveals that AC484 engages in up to nine interactions within the active site. It forms critical hydrogen bonds with residues Cys216, Arg222, Asp182, Ser217, and Ile220. Additionally, an isopentyl-amine group was designed to interact proximal to the tetralin ring, engaging in a hydrogen bond with Asp50 and a hydrophobic interaction with Met256 [1].
A pivotal feature of AC484's SAR is its zwitterionic nature. The compound possesses a thiadiazolidinone dioxide group (NH pKa = 0.9) and an amine group (NH pKa = 10). This specific zwitterionic profile is responsible for its favorable pharmacokinetic properties, including low plasma protein binding (86% unbound in mouse plasma, 50% in human plasma) and low clearance (cleared via renal and biliary mechanisms rather than hepatic). This unique chemical structure allows AC484 to maintain potent cellular activity (STAT1 IC50 of 176 nM in B16 cells) and oral bioavailability, distinguishing it from previous phosphotyrosine mimetics [1].
5. Current Limitations
While AC484 is highly efficacious, there are limitations and safety considerations associated with systemic PTPN2/N1 inhibition. High doses of AC484 (e.g., 100 mg/kg twice daily in mice, or 300 mg/kg/day in rats) can lead to overt systemic immune activation. This manifests as dose-dependent inflammatory immune cell infiltrates in peripheral tissues such as the kidneys, joints, and liver [1]. However, these toxicities are reversible and resolve within weeks of treatment cessation, highlighting a benefit of small-molecule inhibitors over long half-life biologics [1].
Additionally, the direct tumor-growth inhibitory effect of AC484 is highly dependent on an intact IFNγ-sensing pathway within the tumor cells. Cancer cell lines harboring loss-of-function mutations in IFNGR1, IFNGR2, JAK, or STAT genes are intrinsically resistant to AC484-mediated direct growth inhibition in vitro [1]. Although AC484 can still exert anti-tumor effects in vivo by activating immune cells (e.g., NK cells) even in tumors with antigen presentation or JAK1 defects, tumors completely lacking inflammatory signatures may exhibit reduced overall sensitivity [1].
6. Future Perspectives
The development of AC484 opens several promising avenues for future cancer immunotherapy, particularly in the realm of Adoptive Cell Therapy (ACT). Because transient ex vivo exposure to AC484 induces durable epigenetic and metabolic rewiring that prevents T cell exhaustion and enhances in vivo persistence, incorporating AC484 into the manufacturing protocols of CAR-T or TCR-T cells could significantly improve the efficacy of these cellular products against solid tumors [1].
Furthermore, AC484 demonstrates strong potential for combination therapies. Its distinct mechanism of action—enhancing the activity of multiple cytotoxic subsets (CD8+ T cells and NK cells) and overcoming mechanisms of immune evasion like MHC class I loss—makes it an ideal candidate to combine with immune checkpoint inhibitors (e.g., anti-PD-1). Preclinical data already show additive effects when AC484 is combined with PD-1 blockade [1]. As the first active-site phosphatase inhibitor in oncology clinical trials, the success of AC484 may also validate the druggability of other phosphatase targets, spurring a new class of intracellular immune-modulating therapeutics [1] [2].
